{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:52:57Z","timestamp":1788537177277,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T00:00:00Z","timestamp":1548028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003122","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003122","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","rbmojournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive BioMedicine Online"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.rbmo.2018.12.032","type":"journal-article","created":{"date-parts":[[2018,12,23]],"date-time":"2018-12-23T11:54:58Z","timestamp":1545566098000},"page":"528-537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and\/or the need for additional preventive interventions: cumulative data over three stimulation cycles"],"prefix":"10.1016","volume":"38","author":[{"given":"Manuel","family":"Fern\u00e1ndez-S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Visnova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Yuzpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjarke Mirner","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Mannaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan-Carles","family":"Arce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rbmo.2018.12.032_bib0001","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1210\/jc.2007-0409","article-title":"Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction","volume":"92","author":"Alvarez","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.rbmo.2018.12.032_bib0002","series-title":"Anti-M\u00fcllerian Hormone","first-page":"83","article-title":"Using AMH for determining a stratified gonadotrophin dosing regimen for IVF\/ICSI and optimizing outcomes","author":"Arce","year":"2016"},{"key":"10.1016\/j.rbmo.2018.12.032_bib0003","article-title":"Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind phase 3 safety trial","author":"Bosch","year":"2018","journal-title":"Reprod. Biomed. Online."},{"key":"10.1016\/j.rbmo.2018.12.032_bib0004","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/humrep\/deq005","article-title":"The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial","volume":"25","author":"Busso","year":"2010","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2018.12.032_bib0005","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1093\/humrep\/der251","article-title":"An OHSS-free clinic by segmentation of IVF treatment","volume":"26","author":"Devroey","year":"2011","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2018.12.032_bib0006","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.fertnstert.2014.01.019","article-title":"Severe ovarian hyperstimulation syndrome after gonadotrophin-releasing hormone (GnRH) agonist trigger and \u2018freeze-all\u2019 approach in GnRH antagonist protocol","volume":"101","author":"Fatemi","year":"2014","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2018.12.032_bib0007","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.fertnstert.2012.07.1164","article-title":"Best practices of ASRM and ESHRE: a journey through reproductive medicine","volume":"98","author":"Gianaroli","year":"2012","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2018.12.032_bib0008","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00006254-198906000-00004","article-title":"Ovarian hyperstimulation syndrome: an update review","volume":"44","author":"Golan","year":"1989","journal-title":"Obstet. Gynecol. Surv."},{"key":"10.1016\/j.rbmo.2018.12.032_bib0009","author":"Gonal-F"},{"key":"10.1016\/j.rbmo.2018.12.032_bib0010","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.rbmo.2014.07.022","article-title":"Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases","volume":"29","author":"Gurbuz","year":"2014","journal-title":"Reprod. Biomed. Online."},{"key":"10.1016\/j.rbmo.2018.12.032_bib0011","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.fertnstert.2010.03.028","article-title":"Preventing ovarian hyperstimulation syndrome: guidance for the clinician","volume":"94","author":"Humaidan","year":"2010","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2018.12.032_bib0012","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/humrep\/dem254","article-title":"Serum anti-M\u00fcllerian hormone and oestradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles","volume":"23","author":"Lee","year":"2008","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2018.12.032_bib0013","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.rbmo.2014.05.012","article-title":"GnRH agonist trigger and ovarian hyperstimulation syndrome: relook at \u2018freeze-all strategy\u2019","volume":"29","author":"Ling","year":"2014","journal-title":"Reprod. Biomed. Online."},{"key":"10.1016\/j.rbmo.2018.12.032_bib0014","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/14647273.2014.961745","article-title":"British Fertility Society Policy and Practice Committee: Prevention of ovarian hyperstimulation syndrome","volume":"17","author":"Mathur","year":"2014","journal-title":"Hum Fertil (Camb)."},{"issue":"suppl 1","key":"10.1016\/j.rbmo.2018.12.032_bib0015","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S0049-3848(17)30070-1","article-title":"Prevention and management of ovarian hyperstimulation syndrome","volume":"151","author":"Nelson","year":"2017","journal-title":"Thromb. Res."},{"key":"10.1016\/j.rbmo.2018.12.032_bib0016","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.fertnstert.2015.06.024","article-title":"Two new automated, compared with two enzyme-linked immunosorbent, antimullerian hormone assays","volume":"104","author":"Nelson","year":"2015","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2018.12.032_bib0017","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.fertnstert.2016.10.033","article-title":"Individualized versus conventional ovarian stimulation forin vitro fertilization: a multicentre, randomized, controlled, assessor-blinded, phase 3 noninferiority trial","volume":"107","author":"Nyboe Andersen","year":"2017","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2018.12.032_bib0018","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.fertnstert.2016.08.048","article-title":"Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline","volume":"106","year":"2016","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2018.12.032_bib0019","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.fertnstert.2015.06.027","article-title":"Intercycle variability of the ovarian response in patients undergoing repeated stimulation with corifollitropin alfa in a gonadotrophin-releasing hormone antagonist protocol","volume":"104","author":"Rombauts","year":"2015","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2018.12.032_bib0021","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s10815-015-0498-y","article-title":"Ovarian hyperstimulation syndrome after gonadotrophin-releasing hormone agonist triggering and \u2018freeze-all\u2019: in-depth analysis of genetic predisposition","volume":"32","author":"Santos-Ribeiro","year":"2015","journal-title":"J. Assist. Reprod. Genet."},{"key":"10.1016\/j.rbmo.2018.12.032_bib0022","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ."},{"key":"10.1016\/j.rbmo.2018.12.032_bib0023","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/514159","article-title":"Prevention of ovarian hyperstimulation syndrome: a review","volume":"2015","author":"Smith","year":"2015","journal-title":"Obstet. Gynecol. Int."},{"key":"10.1016\/j.rbmo.2018.12.032_bib0024","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/humrep\/dev127","article-title":"Performance of the two new fully automated anti-M\u00fcllerian hormone immunoassays compared with the clinical standard assay","volume":"30","author":"van Helden","year":"2015","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2018.12.032_bib0025","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/humrep\/dex321","article-title":"Individualized FSH dosing based on ovarian reserve testing in women starting IVF\/ICSI: a multicentre trial and cost-effectiveness analysis","volume":"32","author":"van Tilborg","year":"2017","journal-title":"Hum. Reprod."}],"container-title":["Reproductive BioMedicine Online"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472648318306618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472648318306618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T02:43:39Z","timestamp":1565232219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472648318306618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1472648318306618"],"URL":"https:\/\/doi.org\/10.1016\/j.rbmo.2018.12.032","relation":{},"ISSN":["1472-6483"],"issn-type":[{"value":"1472-6483","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and\/or the need for additional preventive interventions: cumulative data over three stimulation cycles","name":"articletitle","label":"Article Title"},{"value":"Reproductive BioMedicine Online","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rbmo.2018.12.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd on behalf of Reproductive Healthcare Ltd.","name":"copyright","label":"Copyright"}]}}